Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxicity of platinum compounds.

Jörg Thomas Hartmann1, Hans-Peter Lipp

  • 1Department of Hematology, Oncology, Immunology, Rheumatology, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany. joerg.hartmann@med.uni-tuebingen.de

Expert Opinion on Pharmacotherapy
|June 5, 2003
PubMed
Summary

Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, has transformed solid tumor treatment. This review compares their efficacy, pharmacokinetics, and side effects, highlighting oxaliplatin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations on Drug Selection and Dose Adjustment for Patients with Liver Cirrhosis: Results from a Multidisciplinary Expert Panel.

Clinical drug investigation·2026
Same author

The cost of language: functionally over-dominant language circuits in the human brain may limit cognitive abilities and non-verbal executive functions.

Frontiers in human neuroscience·2025
Same author

[Androgen receptor-targeted therapies - avoid clinically relevant interactions].

Aktuelle Urologie·2025
Same author

IntelliCage: the development and perspectives of a mouse- and user-friendly automated behavioral test system.

Frontiers in behavioral neuroscience·2024
Same author

Gross Hematuria Associated with Anticoagulants and Antiplatelet Drugs: Analysis of Current Treatment Standards and Relevance of Co-medication and Pharmacological Interactions.

European urology focus·2023
Same author

SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.

Future oncology (London, England)·2023

Area of Science:

  • Oncology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Platinum-based chemotherapy agents, particularly cisplatin, have significantly improved solid tumor treatment outcomes.
  • Cisplatin, carboplatin, and oxaliplatin are the primary platinum compounds used in cancer chemotherapy.
  • These agents exhibit structural similarities but differ in therapeutic applications, pharmacokinetics, and adverse effect profiles.

Purpose of the Study:

  • To review and compare the clinical utility of cisplatin, carboplatin, and oxaliplatin.
  • To highlight the distinct therapeutic roles and characteristics of these key platinum-based chemotherapy drugs.
  • To provide an overview of emerging platinum compounds under investigation.

Main Methods:

  • Literature review of clinical studies and pharmacological data.
  • Comparative analysis of efficacy, pharmacokinetics, and toxicity profiles.
  • Focus on cisplatin, carboplatin, and oxaliplatin, with mention of other investigational agents.

Main Results:

  • Carboplatin shows comparable efficacy to cisplatin in lung and ovarian cancers but is less effective in germ-cell, head and neck, bladder, and esophageal cancers.
  • Oxaliplatin demonstrates significant efficacy in colorectal cancer when combined with 5-fluorouracil and folinic acid.
  • Several other platinum compounds are under investigation, while nedaplatin is approved in Japan.

Conclusions:

  • Cisplatin, carboplatin, and oxaliplatin represent distinct therapeutic options in solid tumor treatment.
  • Understanding their differential profiles is crucial for optimizing chemotherapy regimens.
  • Ongoing research into novel platinum compounds may offer future treatment advancements.

Related Experiment Videos